Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States

CONCLUSION: Initiation of therapy with a novel treatment is often associated with an increase in overall healthcare costs due to the entrance costs associated with novel therapy. For a chronic condition such as migraine, cost versus health benefits should be evaluated over a long period (e.g., ≥2 years) to better understand the true benefits of therapy. Data from this study suggest that the entrance cost for erenumab, the primary driver of the high post-index prescription costs gets mitigated by reduced medical costs over long-term follow-up. The results indicate better disease management in adult patients with migraine, which should be an important consideration for both patients and payors, as these findings have shown an offset between migraine-related prescription and medical costs.PMID:37655551 | DOI:10.1111/head.14612

Source: Headache - September 1, 2023 Category: Neurology Authors: Stewart J Tepper Todd J Schwedt Pamela Vo Jeffrey Thompson Parth Joshi Ahmad Abdrabboh Matias Ferraris Santosh Tiwari Source Type: research